CLINICAL TRIAL SUMMARY

MDACC Study No:2012-1017 (clinicaltrials.gov NCT No: NCT01786343)
Title:A RANDOMIZED PHASE II STUDY OF TWO SCHEDULES OF DECITABINE FOR FRONTLINE THERAPY OF OLDER OR UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML)
Principal Investigator:Farhad Ravandi-Kashani
Treatment Agent:Decitabine
Study Status:Open
Study Description:The goal of this clinical research study is to compare how well 2 different
dosing schedules of decitabine may help control AML.

Decitabine is designed to damage the DNA (the genetic material) of cells, which
may cause cancer cells to die.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:Decitabine
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Farhad Ravandi-Kashani
Dept:Leukemia
For Clinical Trial Enrollment:713-745-0394
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults